Literature DB >> 22186771

Post-discharge compliance to venous thromboembolism prophylaxis in high-risk orthopaedic surgery: results from the ETHOS registry.

David Bergqvist1, Juan I Arcelus, Paulo Felicissimo.   

Abstract

Venous thromboembolism (VTE) risk persists for several weeks following high-risk orthopaedic surgery (HROS). The ETHOS registry evaluated post-operative VTE prophylaxis prescribed, and actual VTE prophylaxis received, compared with the 2004 American College of Chest Physicians (ACCP) guidelines in HROS patients. We performed a subanalysis of ETHOS to assess patient compliance with ACCP-adherent prophylaxis after discharge and the factors predicting poor compliance. Consecutive patients undergoing hip fracture surgery, total hip arthroplasty, or knee arthroplasty were enrolled at discharge from 161 centres in 17 European countries if they had received adequate in-hospital VTE prophylaxis. Data on prescribed and actual prophylaxis received were obtained from hospital charts and patient post-discharge diaries. Good compliance was defined as percentage treatment intake ≥80% with no more than two consecutive days without treatment. A total of 3,484 patients (79.4%) received ACCP-adherent anticoagulant prescription at discharge and 2,999 (86.0%) had an evaluable patient diary. In total, 87.7% of evaluable patients were compliant with prescribed treatment after discharge. The most common reason for non-compliance (33.4%) was "drug was not bought". Injection of treatment was not a barrier to good compliance. Main factors affecting compliance related to purchase of and access to treatment, patient education, the person responsible for administering injections, country, and type of hospital ward at discharge. Within our study population, patient compliance with ACCP-adherent thromboprophylaxis prescribed at discharge was good. Improvements in patient education and prescribing practices at discharge may be important in further raising compliance levels in high-risk orthopaedic surgery patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22186771     DOI: 10.1160/TH11-07-0464

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  13 in total

Review 1.  Approaches to prevent bleeding associated with anticoagulants: current status and recent developments.

Authors:  Manu Thomas Kalathottukaren; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

Review 2.  Orthogeriatric co-management for the care of older subjects with hip fracture: recommendations from an Italian intersociety consensus.

Authors:  Antonio De Vincentis; Astrid Ursula Behr; Giuseppe Bellelli; Marco Bravi; Anna Castaldo; Lucia Galluzzo; Giovanni Iolascon; Stefania Maggi; Emilio Martini; Alberto Momoli; Graziano Onder; Marco Paoletta; Luca Pietrogrande; Mauro Roselli; Mauro Ruggeri; Carmelinda Ruggiero; Fabio Santacaterina; Luigi Tritapepe; Amedeo Zurlo; Raffaele Antonelli Incalzi
Journal:  Aging Clin Exp Res       Date:  2021-07-21       Impact factor: 3.636

3.  Do Cost Limitations of Extended Prophylaxis After Surgery Apply to Ulcerative Colitis Patients?

Authors:  Ira L Leeds; Joseph K Canner; Sandra R DiBrito; Bashar Safar
Journal:  Dis Colon Rectum       Date:  2022-05-01       Impact factor: 4.585

4.  Continuation of venous thromboembolism prophylaxis after hospital discharge into the outpatient setting: the ACCEPT study.

Authors:  Sebastian M Schellong; Jürgen Kaiser; Peter Bramlage
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

5.  Defining high risk: cost-effectiveness of extended-duration thromboprophylaxis following major oncologic abdominal surgery.

Authors:  James C Iannuzzi; Aaron S Rickles; Kristin N Kelly; Fergal J Fleming; James G Dolan; John R T Monson; Katia Noyes
Journal:  J Gastrointest Surg       Date:  2013-10-08       Impact factor: 3.452

6.  Patient Adherence and Experience with Extended Use of Prophylactic Low-Molecular-Weight Heparin Following Pancreas and Liver Resection.

Authors:  Madeline Lemke; Kaitlyn Beyfuss; Julie Hallet; Natalie G Coburn; Calvin H L Law; Paul J Karanicolas
Journal:  J Gastrointest Surg       Date:  2016-09-29       Impact factor: 3.452

7.  Dabigatran (Pradaxa) Is Safe for Extended Venous Thromboembolism Prophylaxis After Surgery for Pancreatic Cancer.

Authors:  M Farzan Rashid; Terri L Jackson; Jheanell A Morgan; Franklin A Dwyer; Beth A Schrope; John A Chabot; Michael D Kluger
Journal:  J Gastrointest Surg       Date:  2018-09-05       Impact factor: 3.452

8.  Cost-Benefit Limitations of Extended, Outpatient Venous Thromboembolism Prophylaxis Following Surgery for Crohn's Disease.

Authors:  Ira L Leeds; Sandra R DiBrito; Joseph K Canner; Elliott R Haut; Bashar Safar
Journal:  Dis Colon Rectum       Date:  2019-11       Impact factor: 4.585

9.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.

Authors:  Seth Felder; Morten Schnack Rasmussen; Ray King; Bradford Sklow; Mary Kwaan; Robert Madoff; Christine Jensen
Journal:  Cochrane Database Syst Rev       Date:  2019-03-27

10.  Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery.

Authors:  Seth Felder; Morten Schnack Rasmussen; Ray King; Bradford Sklow; Mary Kwaan; Robert Madoff; Christine Jensen
Journal:  Cochrane Database Syst Rev       Date:  2019-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.